65,437 trials
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c at Week 52 — -0.67; -0.67 Percent
Basal Cell Carcinoma
Primary: Clinical Response to Photodynamic Therapy — 9; 14; 5 lesions
Hypertension
Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure — -6.48; -9.24; -9.33 mmHg — p=<0.0001
Diabetes · Diabetes Mellitus, Type 2
Primary: Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7% — 64.3; 54.5 percentage of participants — p=0.0411
Therapeutic Equivalency, Healthy
Primary: Maximum Plasma Concentration (Cmax) — 565.52; 570.60 ng/mL
Diabetes Mellitus
Primary: Number of Capillary and Venous Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method — 273; 274; 280; 273 number of blood glucose (BG) results
Therapeutic Equivalency
Primary: Maximum Plasma Concentration (Cmax) — 484.895; 472.689 ng/mL
Carcinoma, Renal Cell
Primary: Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST) — 14 participants
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 92; 94 Participants
Healthy Volunteers
Primary: Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1 — -3.37; 12.96; -0.94; -0.91 msec
Male Osteoporosis
Primary: Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12 — .94; 3.52 percent — p=<0.001
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast) — 7356.3; 9502.1; 6496.0; 1320.7 ng*hr/mL
Myocardial Ischemia · Acute Coronary Syndrome
Primary: Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. — 9.3; 10.0…
Pharyngitis
Primary: Visual Analogue Scale(0-100mm) by the Subject. — 51; 40; 22; 9 mm
Diabetic Neuropathies
Primary: Change From Baseline (Week 8) in Brief Pain Inventory (BPI) 24-hour Average Pain Item Score at Week 34 Endpoint — 0.35 units on a scale — p=<0.001